Search for a trial

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock

To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.

pharmacokinetic-pharmacodynamic modeling of S(+)-ketamine in fibromyalgia

To test the hypothesis that ketamine has a modulatory effect on fibromyalgia

Protein intake, gastro-Intestinal tolerance and safety after administration of a new high protein tube feed in critically ill overweight ICU patients as compared to an isocaloric standard tube feed.

As meeting protein requirements seems to be very important in critically ill patients, the primary objective of the current study is to investigate protein intake with the new tube feed.